Vyome (NASDAQ:HIND) Posts Quarterly Earnings Results

Vyome (NASDAQ:HIND) posted its earnings results on Wednesday. The company reported ($0.10) earnings per share for the quarter, Zacks reports.

Vyome Stock Down 1.3%

NASDAQ HIND traded down $0.03 during trading hours on Wednesday, hitting $2.22. 11,490 shares of the stock were exchanged, compared to its average volume of 360,629. The company has a market cap of $15.58 million, a price-to-earnings ratio of -0.18 and a beta of 1.48. Vyome has a 12-month low of $1.75 and a 12-month high of $18.60. The stock has a 50-day moving average of $2.17 and a 200 day moving average of $2.32.

Hedge Funds Weigh In On Vyome

A hedge fund recently bought a new stake in Vyome stock. Millennium Management LLC bought a new position in shares of Vyome Holdings, Inc. (NASDAQ:HIND) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 45,144 shares of the company’s stock, valued at approximately $155,000. Millennium Management LLC owned approximately 0.80% of Vyome at the end of the most recent quarter. Hedge funds and other institutional investors own 22.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on HIND shares. Zacks Research upgraded shares of Vyome to a “hold” rating in a research note on Wednesday, May 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Vyome in a report on Wednesday, July 29th. Finally, Litchfield Hills Research started coverage on shares of Vyome in a research report on Monday, May 4th. They issued a “buy” rating on the stock. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $15.00.

About Vyome

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.